Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$37.26 USD

37.26
5,806,710

+1.04 (2.87%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $37.26 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane

by Zacks Equity Research

BAYRY files for FDA nod to gadoquatrane, a low-dose MRI contrast agent backed by strong QUANTI study results.

Zacks Equity Research

Here's Why Exelixis (EXEL) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

EXEL or ARGX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis

by Zacks Equity Research

FLEX, CVS, URBN and EXEL stand out as GARP picks with strong growth outlooks and discounted PEG ratios.

Urmimala Biswas headshot

4 Attractive GARP Picks for Your Portfolio Based on PEG Ratio

by Urmimala Biswas

Here are four discounted PEG stocks that qualify our screening criteria and could be good picks. These are FLEX, CVS, URBN and EXEL.

Zacks Equity Research

Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ethan Feller headshot

3 Underfollowed Stocks on the Move Now (OLO, PLMR, EXEL)

by Ethan Feller

Palomar Holdings, Exelixis and Olo stocks all boast top Zacks Ranks, reasonable valuations and strong price momentum

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

by Zacks Equity Research

Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice

by Zacks Equity Research

Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?

by Zacks Equity Research

EXEL gains 28.2% YTD, driven by Cabometyx growth, pipeline progress and an increase in stock buyback authorizations.

Zacks Equity Research

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Sanghamitra Saha headshot

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

by Sanghamitra Saha

Top-ranked stocks Urban Outfitters (URBN), Tenet Healthcare (THC), Five9 (FIVN), Marqeta (MQ) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases.

Zacks Equity Research

Here's Why Exelixis (EXEL) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Urmimala Biswas headshot

Top 4 Value Stocks With Impressive PEG Ratios to Buy Now

by Urmimala Biswas

Here are the four discounted PEG-based value stocks that qualify our screening criteria- URBN, XRAY, LTM and EXEL.

Zacks Equity Research

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

by Zacks Equity Research

Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?

by Zacks Equity Research

Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

by Zacks Equity Research

Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.

Zacks Equity Research

Exelixis (EXEL) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and Prospects

by Zacks Equity Research

Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Zacks Equity Research

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Company News for May 15, 2025

by Zacks Equity Research

Companies in The News Are: ARCO,DT,EXEL,ALC